Level of Serum Adiponectin in Sjögren’s Syndrome

Objective: To evaluate the serum adiponectin level and determine the association between adiponectin and various clinical and laboratory findings in patients with primary Sjögren's syndrome (pSS). Materials and Methods: A total of 50 patients and 30 healthy volunteers were enrolled in the present study. Serum adiponectin levels were detected by colorimetric enzyme-linked immunosorbent assay. The medical history of patients including complete blood count analysis; high sensitive C-reactive protein; erythrocyte sedimentation rate (ESR); complement component 3; complement component 4; low density lipoprotein cholesterol; triglyceride; immunoglobulin G (IgG), IgA, and IgM levels; and the status of Ro 60, Ro 52, Sjögren's syndrome A, Sjögren's syndrome B, and rheumatoid factor were obtained from laboratory information system. Results: Serum adiponectin levels were 2.34 (0.77–4.95) ng/mL and 1.73 (0.01–7.76) ng/mL in patients and controls, respectively (p=0.316). Positive correlation was observed between the values of serum adiponectin, ESR (p=0.013, rho=0.362), and body mass index (p=0.018, rho=0.362) in patients. Conclusion: These findings indicate that adiponectin does not play a crucial role in the immunological and clinical patterns of pSS.